• Acceleron Pharma

  Acceleron is a privately-held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel protein therapeutics for orphan diseases and cancer.

• Acorda Therapeutics

  Acorda Therapeutics (ACOR) is a biotechnology company developing therapies for multiple sclerosis, spinal cord injury and related nervous system disorders.

• Agios Pharmaceuticals

  Agios Pharmaceuticals is the first biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the emerging field of cancer metabolism.

• Alkermes

  Alkermes (ALKS) is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives.

• Allos Therapeutics

  Allos Therapeutics (ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics.

• Alnylam Pharmaceuticals

  Alnylam (ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.

• AMAG Pharmaceuticals

  AMAG Pharmaceuticals (AMAG) is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia.

• Avila Therapeutics

  Avila Therapeutics is a clinical?stage biotechnology company focused on the design and development of targeted covalent drugs to achieve best?in class outcomes.

• BioSpecifics Technologies

  BioSpecifics Technologies (BSTC) is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, five of which include: Dupuytren's contracture; Peyronie's disease; Frozen Shoulder (Adhesive Capsulitis) and human and canine lipoma.

• Curis

  Curis (CRIS) is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer.

• Endocyte

  Endocyte (ECYT) is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. We use our proprietary technology to create novel small molecule drug conjugates, or SMDCs.

• Gevo

  Gevo (GEVO) is retrofitting existing ethanol plants into biorefineries to convert renewable raw materials into isobutanol and renewable hydrocarbons for the chemical and fuel industries.

• ImmunoGen

  ImmunoGen (IMGN) develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers.

• Infinity Pharmaceuticals

  Infinity (INFI) is an innovative drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways

• Ironwood Pharmaceuticals

  Ironwood Pharmaceuticals (IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking.

• Mascoma Corporation

  Mascoma Corporation is a renewable fuels company that has developed innovative technology for the low-cost conversion of abundant biomass.

• Mesoblast

  Mesoblast Limited (MSB.AX) is a world leader in commercializing biologic products for the broad field of regenerative medicine.

• Millennium

  The Takeda Oncology Company, is a leading biopharmaceutical company that markets VELCADE, a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of oncology product candidates.

• Mission New Energy

  Mission NewEnergy Limited (MNEL) is a global provider of sustainable, renewable energy. Operating in Asia, India, Australia, Europe and North America, Mission NewEnergy is a biodiesel producer and one of the world’s largest Jatropha plantation companies.

• Momenta Pharmaceuticals

  Momenta Pharmaceuticals (MNTA) is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs.

• Rexahn Pharmaceuticals

  Rexahn Pharmaceuticals (RNN) is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs

• SciClone Pharmaceuticals

  SciClone Pharmaceuticals (SCLN) is a revenue-generating, profitable, China-centric specialty pharmaceutical company with a substantial commercial business and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders.

• SkinMedica

  SkinMedica, Inc. is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products.

• Tengion

  Tengion (TNGN), a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform(TM) that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues.

• Verenium

  Verenium (VRNM), an industrial biotechnology company, is a global leader in developing high-performance enzymes. Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.

Alkermes Deep Dive Analyst and Investor Day on July 18th, 2011